We Will Toss Lilly On The Pile, As Well -- With Insulin Products In Focus...

So. . . here is the Lilly version, for Q3 2023. And it is. . . right in line with everyone, except. . . Pfizer, as adjusted for size of entity. [That is, Pfizer's spend is. . . outsized.]

This is the detail -- on Lilly's spend, through three-quarters of 2023 -- and plainly, the focus here is protecting insulin pricing, indeed:

. . .Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil. . . .

[Senate] Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act. . . .

[House] Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act. . . .

Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access. . . .

Pharmaceutical intellectual property issues. . . .

Implementation of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax. . . .

Hospital discounts; 340B program. . . .

Now you are in the know -- Lilly obviously focuses on preserving government payor/reimbursement levels, for its insulin products. That, and justifying the vast price increases seen over the last decade in the diabetes therapies regimens. Smile. Merck and Amazon's health spend -- yet to come, this week. Onward.

नमस्ते